

09 / 529050  
422 Rec'd Puff/PTO 75 APR 2000

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Attorney Docket No.</b> <b>PU3375USW</b>	<b>International Appln. No.</b> <b>PCT/EP98/06278</b>
	<b>APPLICANT</b> <b>MANGEL, et al.</b>	
	<b>International Filing Date</b> <b>October 5, 1998</b>	<b>GROUP</b> <i>1614</i>

## **U.S. PATENT DOCUMENTS**

**Continue on page**

## **FOREIGN PATENT DOCUMENTS**

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
PS	BK	W089 09217A	5 Oct 1989	PCT			
PS	BL	EP 0336759 A	11 Oct 1989	EP			
PS	BM	EP 0254584A	27 Jan 1988	EP			
PS	BN	EP 0279512A	24 Aug 1988	EP			
PS	BO	EP 0315390A	10 May 1989	EP			
PS	BP	WO94 01095A	20 Jan 1994	PCT			
PS	BQ	EP 0306323 A	8 Mar 1989	EP			

**Continue on page**

**OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)**

---

Continue on page

EXAMINER	Continue on page _____
<i>Phyllis Spivack</i>	DATE CONSIDERED <u>8/25/00</u>

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

09/529050

422 Rec'd PCT/PTO J 5 APR 2000

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				Attorney Docket No. PU3375USW	International Appln. No. PCT/EP98/06278		
				APPLICANT MANGEL, et al.			
#4				International Filing Date October 5, 1998	GROUP 1614		
U.S. PATENT DOCUMENTS							

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
-------------------	--	---------------	------------	------	-------	----------	----------------------------

Continue on page \_\_\_\_\_

## FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
PS	BA	WO92 12149A	23 Jul 1992	PCT			
PS	BB	WO92 11259A	9 Jul 1992	PCT			
PS	BC	WO92 10494A	25 Jun 1992	PCT			
PS	BD	EP0387431 A	19 Sep 1990	EP			
PS	BE	WO92 05174A	2 Apr 1992	PCT			
PS	BF	EP0377967 A	18 Jul 1990	EP			
PS	BG	EP0385722 A	5 Sept 1990	EP			
PS	BH	EP0364274 A	18 Apr 1990	EP			
PS	BI	EP0357416 A	7 Mar 1990	EP			
PS	BJ	EP0347229 A	20 Dec 1989	EP			

Continue on page 2

## OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

PS	CA	"new product makes a difference", M Magnet, The magazine for Glaxo Wellcome plc staff, page 6, July 1997.
PS	CB	"For Women Only", rubicon, page 9, August 1997.
PS	CC	K. Bardhan et al, "A Double-Blind Placebo-Controlled Study to Evaluate The Irritable Bowel Syndrome (IBS)" Gastroenterology, Vol. 110, No. 4, April 1996, pp A630 .
PS	CD	J Foster et al., "Alosetron Slows Colonic Transit in Patients With Irritable Bowel Syndrome (IBS)" Gastroenterology, Vol. 112, 11-14, May 1997, pg. A732 .
PS	CE	D.G. Maxton et al., "Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?", ALIMENT. PHARMACOL. THER., Vol. 10, no. 4, Aug 1996, pp 595-599.
PS	CF	J. Zighelboim et al.: "Visceral Perception in Irritable Bowel Syndrome", DIG.SIS.SCI., Vol. 40, No. 4, April 1995, pp 819-827.
PS	CG	C.J. Steadman et al., "Selective 5-Hydroxytryptamine Type 3 Receptor Antagonism with Ondansetron as Treatment for Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study", MAYO CLINIC PROC., Vol. 67, no. 8, August 1992 pp 732-738 .
PS	CH	P.H. Hsyu et al, "Safety and Age, Gender, and Time Dependent Pharmacokinetics of Alosetron", PHARMACEUTICAL RESEARCH, Vol. 12, no. 9 Suppl., Sept. 1995, page S387.
PS	CI	M. Delvaux et al., "Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome", ALIMENT. PHARMACOL. THER., Vol. 12, no. 9, September 1998, pp849-855.
PS	CJ	R. Berkow et al., "The Merck Manual of Diagnosis and Therapy, 16 <sup>th</sup> edition" 1992, MERCK RESEARCH LABORATORIES, Rahway, N.J.

Continue on page 2

EXAMINER <i>Phyllis Spivack</i>	DATE CONSIDERED <i>4/25/00</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	